Back to search

Netherlands· NL-e83d93b49946

Xultophy 100 eenheden/ml + 3,6 mg/ml oplossing voor injectie

A insulin degludec and liraglutide product containing insuline degludec + liraglutide, registered in Netherlands by Novo Nordisk A.S.. The same ATC class is registered in 12 of our 19 countries.

ATC A10AE56

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedXultophy 100 eenheden/ml + 3,6 mg/ml …ATCA10AE56REGISTER NO.NL-e83d93b49946PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Insulin degludec and liraglutide is registered in 12 of 19 countries.

Countries holding a registration under ATC A10AE56 (insulin degludec and liraglutide), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 8 of them publish a price we can compare per daily dose

Insulin degludec and liraglutide · ATC A10AE56

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
INSULINE DEGLUDEC + LIRAGLUTIDE
Manufacturer
Novo Nordisk A.S.
Country
Netherlands (NL)
ATC code
A10AE56
ATC class
Insulin degludec and liraglutide
Defined daily dose
40 E, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/14/947

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Insulin degludec and liraglutide in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All insulin degludec and liraglutide products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • Iceland · Xultophy
  • Norway · Xultophy

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/325c108f-e5f4-4475-a50c-5b12f948ddaa
GET /v1/drugs/325c108f-e5f4-4475-a50c-5b12f948ddaa?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Oplossing voor injectie",
  "route": "Subcutaan gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/xultophy-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Insulin degludec and liraglutide",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp113858",
  "excipients": [
    "FENOL",
    "GLYCEROL (E 422)",
    "NATRIUMHYDROXIDE (E 524)",
    "WATER VOOR INJECTIE",
    "ZINKDIACETAAT 2-WATER (E 650)",
    "ZOUTZUUR (E 507)"
  ],
  "substances": [
    "INSULINE DEGLUDEC",
    "LIRAGLUTIDE"
  ],
  "leaflet_url": null,
  "authorised_at": "2014/09/18",
  "procedure_number": "EMEA/H/C/002647",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/14/947",
  "additional_monitoring": "N"
}

See everything about insulin degludec and liraglutide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.